Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoarthritis (OA) of the Knee Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CNTX-4975-05, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 22, 2026, 7:27 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

NCT05838742
View directory record Official record
Conditions
Pain, Osteoarthritis, Knee
Interventions
GSK3858279, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Cerritos, California • Huntington Beach, California • Santa Clara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 7:27 AM EDT
Terminated Phase 3 Interventional Results available

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

NCT03349645
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
4 mL injection of AMPION™
Biological
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Encinitas, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Effects of tDCS and tUS on Pain Perception in OA of the Knee

NCT02330315
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis
Interventions
transcranial direct current stimulation (tDCS), transcranial ultrasound (TUS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

NCT03661996
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump
Drug · Device
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Core Activation and Stabilization for Knee OA

NCT03776981
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Core Activation, Core Stabilization
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 22, 2026, 7:27 AM EDT
Terminated Not applicable Interventional

Native Alignment in the Setting of an Arthritic Knee in Total Knee Arthroplasty

NCT06617338
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
CT scan unilateral knee, CT scan bilateral knee
Diagnostic Test
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 7:27 AM EDT
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 3 Interventional

Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee

NCT00722852
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ketoprofen in Diractin®, Placebo
Drug
Lead sponsor
IDEA AG
Industry
Eligibility
46 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2009 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
View directory record Official record
Conditions
Bilateral Knee Osteoarthritis
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Torrance, California • Rochester, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection

NCT01895959
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Euflexxa, Magnetic Resonance Imaging (MRI)
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

NCT03291470
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 7:27 AM EDT
Terminated Not applicable Interventional Results available

Optimization of Synvisc-One for Knee OA

NCT02029703
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Synvisc-One Injection, Sham Injection
Device · Other
Lead sponsor
Elaine Husni
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Virtual Reality and Older Adult Knee OA

NCT04951661
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Virtual Reality
Device
Lead sponsor
Tufts University
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA

NCT03895840
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Zilretta
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 1 Interventional

Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA

NCT02790723
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
sc-rAAV2.5IL-1Ra
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

NCT01688934
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 7:27 AM EDT
Recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471
View directory record Official record
Conditions
Osteoarthritis
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
26
States / cities
Phoenix, Arizona • Tempe, Arizona • Huntington Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

NCT02768155
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Amniotic Fluid 4.0ml dose, Amniotic Fluid 2.0ml dose, Placebo Control
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
30 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee

NCT02068599
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Anaheim, California • Cerritos, California • El Cajon, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

NCT01709214
View directory record Official record
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 22, 2026, 7:27 AM EDT
Recruiting Not applicable Interventional

Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy

NCT06893302
View directory record Official record
Conditions
Chondral Lesion of the Knee, Meniscal Injuries, Cartilage Defects of the Knee, Osteoarthritis (OA) of the Knee
Interventions
Bone Marrow Aspirate (BMA), Arthroscopic Debridement Surgery, Saline
Biological · Procedure · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 7:27 AM EDT
Completed Phase 2 Interventional

HKT-500-US12 In Adult Patients With OA Knee Pain

NCT00647231
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
HKT-500 Topical Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Jul 22, 2026, 7:27 AM EDT